IIb's are not IIb's

American Journal of Cardiology

Volumn 85, Issue 8 SUPPL. 1, 2000, Pages 23-31

  Kereiakes, Dean J ^a   Runyon, John Paul ^b,c   Broderick, Thomas M ^b   Shimshak, Thomas M ^a,c  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Ohio Heart and Vascular Center   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CD11B ANTIGEN; CD18 ANTIGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; VITRONECTIN RECEPTOR;

ANTICOAGULANT THERAPY; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0034720135     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00876-6     Document Type: Article

References (50)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994:330;956-961.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
3. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
4. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
5. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
6. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998;339:436-443.
7. Kereiakes D.J., Broderick T.M., Roth E.M., Whang D.D., Shimshak T., Runyon J.P., Hattemer C., Schneider J., Lacock P., Mueller M.N., Abbottsmith C.W. Time course, magnitude and consistency of platelet inhibition of abciximab, tirofiban or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 84:1999;391-395.
8. Scarborough R.M., Kleiman N.S., Phillips D.R. Platelet glycoproteins IIb/IIIa antagonists What are the relevant issues concerning their pharmacology and clinical use? Circulation. 100:1999;437-444.
9. Quinn M., Deering A., Stewart M., Cox D., Foley B., Fitzgerald D. Quantifying GP IIb/IIIa receptor binding using 2 monoclonal antibodies. Circulation. 99:1999;2231-2238.
10. Kereiakes DJ, Lincoff AM, Tcheng J, Topol EJ. GP IIb/IIIa blockage during coronary intervention for unstable angina: longer is not better (abstract). Am J Cardiol 1998;82;95S.
11. Coller B.S., Anderson K., Weisman H.F. New antiplatelet agents platelet GP IIb/IIIa antagonists . Thromb Haemost. 74:1995;302-308.
12. Haas T.A., Plow E.F. The cytoplasmic domain of αIIbβ3 a ternary complex of the integrin A and B subunits and a divalent cation . J Biol Chem. 271:1996;6017-6026.
13. Nakada MT, Tam SH, Sassoli PM, Jordan RE. The rapid on-rate and in vitro binding of abciximab to platelets is unaffected by a small molecule GP IIb/IIIa antagonist (abstract). Am J Cardiol 1998;82:96S.
14. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIa receptor blockade. Circulation. 97:1998;1680-1688.
15. Boersma E., Akkerhuis M., Theroux P., Califf R.M., Topol E.J., Simoons M.L. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes early benefit during medical treatment only, with additional protection during percutaneous coronary intervention . Circulation. 100:1999;2045-2048.
16. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
17. Kereiakes D.J., Mueller M., Howard W., Lacock P., Anderson L.C., Broderick T.M., Roth E.M., Abbottsmith C.W. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombol. 7:1999;265-275.
18. Wencel-Drake J., Plow E., Zimmerman T., Painter R., Ginsberg M. Immuno-fluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelet. Am J Pathol. 115:1984;156-164.
19. Steinhubl S.R., Kottke-Marchant K., Moliterno D.J., Rosenthal M.L., Godfrey N.K., Coller B.S., Topol E.J., Lincoff A.M. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 100:1999;1977-1982.
20. Steinhubl S, Talley D, Kereiakes DJ, Breden G, Tcheng J, Casterella P, Moliterno D, Berger P, Popma J, Dangas G, et al. A prospective multicenter study to access the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention: the GOLD study (abstract). J Am Coll Cardiol 2000;35:4A.
21. Coller B.S. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J. 138:(suppl):1999;S1-S5.
22. Coller B.S. Binding of abciximab to αVβ3 and activated αMβ2 receptors with a review of platelet-leukocyte interactions . Thromb Haemost. 82:1999;326-335.
23. Kassirer M., Zeltser D., Prochorov V., Schoenman G., Frimerman A., Keren G., Shapira I., Miller H., Roth A., Arber N., Eldor A., Berliner S. Increased expression of the CD 11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease further evidence for smoldering inflammation in patients with atherosclerosis . Am Heart J. 138:1999;555-559.
24. Mickelson J.K., Ali M.N., Kleiman N.S., Lakkis N.M., Chow T.W., Hughes B.J., Smith C.W. Chimeric 7E3 Fab (ReoPro) decreases detectable CDllb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 33:1999;97-106.
25. Farb A., Sangiorgi G., Carter A.J., Walley V.M., Edwards W.D., Schwartz R.S., Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52.
26. Grewe P.H., Deneke T., Machraoui A., Barmeyer J., Muller K.M. Acute and chronic tissue response to coronary stent implantation pathologic findings in human specimen . J Am Coll Cardiol. 35:2000;157-163.
27. Palmerini T, Nedelman MA, Scudder LE, Nakada MT, Jordon RE, Fallon JT, Coller BS. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates (abstract). J Am Coll Cardiol 1999:100:I-857.
28. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation (abstract). J Am Coll Cardiol 1999;100:I-681.
29. Schwarz M, Kohler B, Nordt T, Ruef J, Bode C, Karlheinz P. Abciximab binds to the leukocyte integrin Mac-1 (CD11b/CD18, αM2) and thereby results in a functional blockade in vitro and in vivo (abstract). J Am Coll Cardiol 1999;100:I-333.
30. Tam S.H., Sassoli P.M., Jordan R.E., Nakada M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 98:1998;1085-1091.
31. Byzova T.V., Rabbani R., D'Souza S.E., Plow E.F. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost. 80:1998;726-734.
32. Hoshiga M., Alpers C.E., Smith L.L., Giachelli C.M., Schwartz S.M. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 77:1995;1129-1135.
33. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:1994;569-571.
34. Stouffer G.A., Hu Z., Sajid M., Li H., Jin G., Nakada M.T., Hanson S.R., Runge M.S. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 97:1998;907-915.
35. Srivatsa S.S., Fitzpatrick L.A., Tsao P.W., Reilly T.M., Holmes D.R., Schwartz R.S. Mousa SA. Selective αVβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αVβ3 and osteopontin expression during neointima formation. Cardiovasc Res. 36:1997;408-428.
36. Bishop, GA, McPherson JA, Sanders J, Feldman MJ, Gimple LW, Ragosta M, Powers ER, Mousa SA, Sarembock IJ. αVβ3 receptor blockade reduces restenosis following balloon angioplasty in the atherosclerotic rabbit (abstract). J Am Coll Cardiol 1999;33:31A.
37. Lincoff AM, Moliterno DJ, Ellis SG, Debowey D, Cabot CF, Booth JE, Godfrey NK, Topol EJ. Six month angiographic outcome with abciximab and stents: the EPISTENT angiographic substudy (abstract). Circulation 1998;98:I:768.
38. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ, for the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-327.
39. Gibson C.M., Goel M., Cohen D.J., Piana R.N., Deckelbaum L.I., Harris K.E., King S.B. III. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol. 32:1998;28-34.
40. Byzova T.V., Plow E.F. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol. 143:1998;2081-2092.
41. Reverter J.C., Beguin S., Kessels H., Dumar R., Hember H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 antibody; potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis. " J Clin Invest. 98:1996;863-874.
42. Li Y, Spencer FA, Becker RC. Synergistic effects of GP IIb/IIIa antagonists and heparin on platelet-dependent procoagulant activity and thrombin generation (abstract). Circulation 1999;100:I-303.
43. Steinhubl SR, Lauer MS, Mukerjee DP, Moliterno DJ, Ellis SG. Pre-treatment with ticlopidine reduces non Q-wave myocardial infarctions following intra-coronary stenting. (abstract). J Am Coll Cardiol 1998;31:100A.
44. Steinhubl SR, Balog C, Topol EJ. Pretreatment with ticlopidine prior to stenting is associated with a substantial decrease in complications: data from the EPISTENT trial (abstract). Circulation 1998;98:I-573.
45. Lincoff AM, Topol EJ. Overview of the glycoprotein IIb/IIIa inhibitor interventional trials. In: Lincoff AM, Topol EJ, eds. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ: Humana Press, 1999,169-197.
46. Bhatt DL, Lincoff AM, Califf RM, Simoons ML, Tcheng JE, Brener SJ, Wolski KE, Topol EJ. The benefit of abciximab in interventional cardiology is not device-specific. Am J Cardiol 2000 (in press).
47. Anderson KM, Ferguson JJ, Stoner GL, Cabot CF, Weisman HF. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention (PCI) (abstract). Circulation 1997;96:I-63.
48. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson K, Califf RM, on behalf of the EPISTENT Investigators. Outcomes of 1 year and economic implications of platelet IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet 1999;354:2019-2024.
49. Kereiakes DJ, Obenchain RL, Barber BL, Cocks D, Smith A, Broderick TM, Roth EM, Whang DD, Shimshak TM, Schneider JF, Abbottsmith CA. Abciximab provides cost effective survival advantage in high volume interventional practice (abstract). Circulation 1999;100:I-733.
50. Kereiakes D.J., McDonald M.A., Broderick T.M., Roth E.M., Whang D.D., Martin L.H., Howard W., Schneider J., Shimshak T.M., Abbottsmith C.A. Platelet glycoprotein IIb/IIIa receptor blockers an appropriate use model for expediting care in acute coronary syndromes . Am Heart Journal. 139:2000;S53-S60.